Navigation Links
ReliantHeart Debuts the VAD Maintenance System at ISHLT, April 15 -17th in Nice, France
Date:4/15/2015

Houston, Texas (PRWEB) April 15, 2015

ReliantHeart, Inc., an innovative supplier of advanced mechanical circulatory assist technologies, and Cathtek, a unique manufacturer of catheters and related accessories, have teamed up to produce the VAD Maintenance System.

Literature review along with a survey of LVAD clinicians conducted in March 2015 reveal that nearly 10% of LVADs occlude with life-threatening thrombus blockage, About 750 to 800 LVADs clotted off in 2014.

LVAD patients suffer greatly from the current treatment options. Two, and only two, approaches are currently available to alleviate thrombus lodged in an LVAD:

(1) Inject a known thrombolytic solution, such as tPA at the inflow of the LVAD. The tPA is delivered via a catheter, however it is not confined to the LVAD and passes through the LVAD. More often than not, tPA causes catastrophic brain bleeds, and any freed thrombus particles may cause stroke.

(2) Exchange the patient’s pump. Pump exchanges are linked to high mortality rates, and are very costly.

“ReliantHeart is proposing a better way as it debuts the VAD Maintenance System at the ISHLT meeting. Not yet in trial, we are presenting what is expected to be the final design. Clinicians will enjoy a close up and personal look at this novel system,” said ReliantHeart COO, Anthony Williams.

The VAD Maintenance System is designed to antiquate existing dangerous and often lethal treatment methods.

Cathtek CEO Todd Cassidy explained: “The VAD Maintenance System includes two co-axial balloon catheters consisting of large inner lumens to aid in evacuating debris. The catheters are introduced through the left and right femoral artery. One catheter will inflate in the inflow side of the LVAD, while the other will inflate in the outflow side. Once the balloons have been properly placed and inflated the LVAD is successfully isolated from the patient’s body.

Once isolation occurs, clinicians have the option of introducing thrombolytic therapies and/or tools that they believe will aid in thrombus removal, all while the LVAD is sequestered from the patient. A final wash out of the LVAD using saline is the last step in restoring the LVAD.”

Clinicians attending ISHLT may visit the ReliantHeart booth for a personal explanation.

IDE Clinical Trial – United States: ReliantHeart Inc. is currently conducting an FDA Investigational Device Exemption (IDE) Clinical Trial on the HeartAssist5® Ventricular Assist Device System. The trial is a prospective, 1:1 randomized, multicenter, clinical trial to evaluate the safety and efficacy of 96 patients implanted with the ReliantHeart HeartAssist5® Ventricular Assist Device (VAD) System compared to 96 patients implanted with either a Thoratec HeartMate II® LVAD or HeartWare HVAD for left ventricular support while awaiting cardiac transplantation. The trial is expected to run through 2016. The HeartAssist5® is a device limited by Federal law to investigational use in the United States.

CE Mark – Europe: ReliantHeart HeartAssist5® Ventricular Assist Device is CE Mark approved for use in patients requiring ventricular support due to end stage heart failure. The HeartAssist5® is approved for bridge to transplant (BTT) patients awaiting cardiac transplantation and for destination therapy (DT) patients who are not candidates for cardiac transplantation.

ReliantHeart, Inc. is an innovative supplier of advanced mechanical circulatory assist technologies that are changing the approach to the treatment of advanced heart failure. It develops and manufactures the HeartAssist5® Ventricular Assist Device. ReliantHeart’s roots are in Houston, Texas, where it has been generously influenced by the transplant centers of Texas Heart, Methodist DeBakey and Memorial Hermann, and its technology originally inspired by NASA, the Johnson Space Center and Baylor School of Medicine.

Cathtek is a medical device manufacturing company founded in 2000, with specialized experience developing catheters and related accessories. Their first hand medical experience influences the design and manufacturing process due to their unique understanding of the needs of the customer and manufacturer , and the ideal choice for the patented ReliantHeart VAD Maintenance System. Cathtek’s experience is broad and runs from product concept, design to prototyping and manufacturing.

Specific areas of experience include insert molding of catheters and components, tipping and various secondary operations associated with catheter manufacturing. Clinical and regulatory experience is a bonus at Cathtek.

Read the full story at http://www.prweb.com/releases/2015/04/prweb12653502.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cleveland Heart Founder Dr. Charles Richardson Appointed to ReliantHeart Board of Directors
2. Houlihan Lokey’s John Soden appointed to ReliantHeart Board of Directors
3. Business Guru Michael E. Gerber appointed to ReliantHeart Board of Directors
4. ReliantHeart Commences FDA Trial on HeartAssist5® VAD
5. LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5®
6. Kollmorgen and ReliantHeart Team Up to Produce Energy Efficient, Wireless LVAD
7. Dualis MedTech and ReliantHeart Partner on Fully Implantable TET System for the HeartAssist5® LVAD
8. Device Solutions and ReliantHeart Collaborate on 3G Wireless Communication for Ventricular Assist Device
9. Leica Microsystems Debuts First 3D Surgical Microscopes with TrueVision® Technology Inside, at AANS Annual Meeting in New Orleans
10. SoundConnect Debuts on Inc. 5000 List of Fastest Growing Companies
11. Bayer CropScience Debuts Serenade Optimum to Help Growers Control Tough Diseases and Combat Resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... Phoenix, Arizona (PRWEB) , ... October 09, 2017 ... ... of Kindred, a four-tiered line of medical marijuana products targeting the needs of ... production and packaging of Kindred takes place in Phoenix, Arizona. , As operators ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ... INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will ... free and open to the public, but registration is required. , WHAT: ...
Breaking Biology Technology:
(Date:6/14/2017)... -- IBM (NYSE: IBM ) is introducing several innovative partner ... developing collaboration between startups and global businesses, taking place in ... event, nine startups will showcase the solutions they have built ... France is one of ... 30 percent increase in the number of startups created between ...
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
Breaking Biology News(10 mins):